RESUMO
No disponible
Assuntos
Humanos , Feminino , Infecções por Citomegalovirus/complicações , Infecções por Citomegalovirus/diagnóstico , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/epidemiologia , Infecções por Citomegalovirus/prevenção & controle , Infecções por Citomegalovirus/fisiopatologia , Programas de Rastreamento/métodosRESUMO
Background. Persistent infection with high-risk human papillomavirus (HR-HPV) has been demonstrated to be the necessary causal factor for developing cervical cancer. To know the most prevalent HR-HPV in different geographical areas is important to design diagnostic tests and implementation of vaccines. Objectives. The goal of this study is to evaluate the prevalence of HR-HPV in a total of 1001 patients, 198 with normal cytology results, 498 with low-grade squamous intraepithelial lesion (LSIL), and 205 with high-grade squamous intraepithelial lesion (HSIL) who attended our gynaecology department for opportunistic screening of HPV infection. Study design. Cervical samples were taken in a PreservCyt vial (Cytyc Corporation, Boxborough, MA). Hybrid capture assay was carried out following the manufacturer's instructions (Digene Corp., Gaithersburg, MD). All samples were further studied with polymerase chain reaction (PCR) (Linear Array HPV Genotyping Test, Roche Diagnostics, Mannheim, Germany). Results. Genotype 16 was the most prevalent HR-HPV in the three groups, 17.8% in the patients with normal cytology results, 22.3% in the LSIL group, and 60% in the HSIL group. Genotype 18 had a very low prevalence in all groups. Other HR-HPV genotypes such as genotype 31, genotype 58 and genotype 52 were found in significant numbers in HSIL patients. Discussion. Our data show that genotypes 16, 31, 58, and 52 are the most prevalent HR-HPV in cervical samples with severe intraepithelial lesion in Spain. There may be some geographical variation in prevalence of carcinogenic types, and it must be considered for designing diagnostic tests and vaccine.
RESUMO
Introducción Se ha demostrado que la detección del ADN del virus del papiloma humano (VPH) es más útil que la citología en la prevención del cáncer cervical especialmente si se identifican los genotipos 16 y 18. Cobas 4800 es un sistema automatizado de PCR a tiempo real que detecta separadamente los genotipos 16 y 18, además de otros 12 genotipos de alto riesgo (AR-VPH)Objetivos Evaluar la detección de AR-VPH con cobas 4800, especialmente los genotipos 16 y 18 y comparar estos resultados con los obtenidos mediante captura de híbridos (HC2). También se evalúa la sensibilidad clínica del cobas 4800 para detectar lesiones >CIN2. Materiales y métodos Se han estudiado 412 muestras cervicales con cobas 4800 y HC2 utilizándose como técnica de referencia una PCR convencional (LA). También se han recogido los resultados citológicos e histológicos de las pacientes Resultados En 376/412 muestras los resultados fueron concordantes (kappa 0,85). En la mayoría de las muestras con resultado positivo por HC2 y negativo por cobas 4800 se detectaron genotipos de bajo riesgo con LA. La sensibilidad y especificidad para la detección de lesiones > CIN2 fueron 92,5 y 44% con cobas 4800 y 88 y 51% con HC2.Conclusión Hay una gran concordancia entre los resultados obtenidos por ambas técnicas. Sin embargo, la CH2 es más inespecífica por tener reactividad cruzada con genotipos de bajo riesgo oncogénico, especialmente el 53. Cobas 4800 presenta la ventaja de identificar los genotipos 16 y 18, además de ser totalmente automatizada y no tener reactividad cruzada con otros genotipos (AU)
Background: It has recently been confirmed that detection of DNA of human papilloma virus (HPV) is more useful than cytology in the screening for cervical cancer, especially if genotypes 16 and 18 are identified. Cobas 4800 is an automated system that detects 14 high risk HPV genotypes: genotypes 16 and 18 separately and 12 other high-risk genotypes pooled.Objectives: The aim of this study is to compare the performance of the cobas 4800 HPV test against the hybrid capture 2 (HC2) and particularly in women in whom >CIN2 lesions are detected Patients and methods: Aliquots from 412 cervical specimens have been studied with three different as says,real time PCR (cobas 4800), Linear Array HPV test, and HC2. Cytological and histological results were also available. Results: There was good agreement between the cobas 4800 and HC2 results in 376 of the 412 women(kappa 0.85). Where there was not good agreement, low-risk HPV genotypes were detected by linear arrayin the majority of samples positive by HC2 and negative by the cobas 4800. Sensitivity and specificity fordetecting >CIN2 lesions were 92.5 and 44%, respectively, by cobas 4800, and 88 and 51% by hybrid capture.Conclusions: In this evaluation the cobas 4800 HPV test was shown to have a similar performance to the HC2 test. However HC2 was less specific due to cross reactivity with low risk genotypes, mainlygenotype 53. Cobas 4800 is very reliable in the detection of high-risk genotypes, with the advantage of simultaneously providing information regarding genotype 16 and 18 infections (AU)
Assuntos
Humanos , Feminino , Papillomavirus Humano 18/isolamento & purificação , Papillomavirus Humano 16/isolamento & purificação , Infecções por Papillomavirus/microbiologia , Neoplasias do Colo do Útero/prevenção & controle , Programas de Rastreamento/métodos , Esfregaço Vaginal , DNA ViralRESUMO
BACKGROUND: It has recently been confirmed that detection of DNA of human papilloma virus (HPV) is more useful than cytology in the screening for cervical cancer, especially if genotypes 16 and 18 are identified. Cobas 4800 is an automated system that detects 14 high risk HPV genotypes: genotypes 16 and 18 separately and 12 other high-risk genotypes pooled. OBJECTIVES: The aim of this study is to compare the performance of the cobas 4800 HPV test against the hybrid capture 2 (HC2) and particularly in women in whom>CIN2 lesions are detected. PATIENTS AND METHODS: Aliquots from 412 cervical specimens have been studied with three different assays, real time PCR (cobas 4800), Linear Array HPV test, and HC2. Cytological and histological results were also available. RESULTS: There was good agreement between the cobas 4800 and HC2 results in 376 of the 412 women (kappa 0.85). Where there was not good agreement, low-risk HPV genotypes were detected by linear array in the majority of samples positive by HC2 and negative by the cobas 4800. Sensitivity and specificity for detecting>CIN2 lesions were 92.5 and 44%, respectively, by cobas 4800, and 88 and 51% by hybrid capture. CONCLUSIONS: In this evaluation the cobas 4800 HPV test was shown to have a similar performance to the HC2 test. However HC2 was less specific due to cross reactivity with low risk genotypes, mainly genotype 53. Cobas 4800 is very reliable in the detection of high-risk genotypes, with the advantage of simultaneously providing information regarding genotype16 and 18 infections.